Sarah Rumple Mahan
Editor-In-Chief
Sarah Rumple Mahan is an award-winning veterinary writer and editor living in Denver, Colorado. Sarah has written for Today’s Veterinary Business since 2018, and she became the publication’s editor-in-chief in 2026. Reach her at smahan@navc.com.

Argenta and Loyal have announced a strategic partnership to advance the early-stage development of LOY-003, an investigational lifespan-extension drug for large-breed dogs.
Loyal’s pipeline targets the underlying mechanisms of canine aging, with LOY-003 specifically designed to regulate growth hormone and IGF-1. Argenta, a global contract development and manufacturing organization (CDMO) dedicated exclusively to animal health, will support the drug’s formulation and process development through its integrated “Molecule to Market” model. The collaboration could expand as the clinical program advances.
Celine Halioua, founder and CEO of Loyal, said that Argenta’s integrated capabilities make them a “strong partner” for the program’s early-stage development. Matt Stober, CEO of Argenta, noted that pioneering programs like LOY-003 align with the CDMO’s model to support novel therapeutic approaches in animal health.
